Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 62 results
Author Title Type [ Year(Desc)]
Filters: Author is Nathan, Carl  [Clear All Filters]
2012
Nathan C.  2012.  Fresh approaches to anti-infective therapies.. Sci Transl Med. 4(140):140sr2.
Wu K, Koo J, Jiang X, Chen R, Cohen SN, Nathan C.  2012.  Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R.. PLoS One. 7(2):e30512.
2013
Nathan C.  2013.  A journey in science: promise, purpose, privilege.. Mol Med. 19(1):305-13.
Lin G, Chidawanyika T, Tsu C, Warrier T, Vaubourgeix J, Blackburn C, Gigstad K, Sintchak M, Dick L, Nathan C.  2013.  N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.. J Am Chem Soc. 135(27):9968-71.
Darby CM, Ingólfsson HI, Jiang X, Shen C, Sun M, Zhao N, Burns K, Liu G, Ehrt S, J Warren D et al..  2013.  Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis.. PLoS One. 8(7):e68942.
2014
Nathan C, Cars O.  2014.  Antibiotic resistance--problems, progress, and prospects.. N Engl J Med. 371(19):1761-3.
2015
Nathan C.  2015.  Cooperative development of antimicrobials: looking back to look ahead.. Nat Rev Microbiol. 13(10):651-7.
Maksymiuk C, Balakrishnan A, Bryk R, Rhee KY, Nathan C.  2015.  E1 of α-ketoglutarate dehydrogenase defends Mycobacterium tuberculosis against glutamate anaplerosis and nitroxidative stress.. Proc Natl Acad Sci U S A. 112(43):E5834-43.
Zhao N, Sun M, Burns-Huang K, Jiang X, Ling Y, Darby C, Ehrt S, Liu G, Nathan C.  2015.  Identification of Rv3852 as an Agrimophol-Binding Protein in Mycobacterium tuberculosis.. PLoS One. 10(5):e0126211.
Vaubourgeix J, Lin G, Dhar N, Chenouard N, Jiang X, Botella H, Lupoli T, Mariani O, Yang G, Ouerfelli O et al..  2015.  Stressed mycobacteria use the chaperone ClpB to sequester irreversibly oxidized proteins asymmetrically within and between cells.. Cell Host Microbe. 17(2):178-90.
Nathan C, Barry CE.  2015.  TB drug development: immunology at the table.. Immunol Rev. 264(1):308-18.
Nathan C.  2015.  What can immunology contribute to the control of the world's leading cause of death from bacterial infection? Immunol Rev. 264(1):2-5.
2016
Karreci ESula, Fan H, Uehara M, Mihali AB, Singh PK, Kurdi AT, Solhjou Z, Riella LV, Ghobrial I, Laragione T et al..  2016.  Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice.. Proc Natl Acad Sci U S A. 113(52):E8425-E8432.
Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, Nandakumar M, Park S, Gold B, Mi J et al..  2016.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 113(31):E4523-30.
Gold B, Smith R, Nguyen Q, Roberts J, Ling Y, Quezada LLopez, Somersan S, Warrier T, Little D, Pingle M et al..  2016.  Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis.. J Med Chem. 59(13):6027-44.
Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al..  2016.  Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.
Lupoli TJ, Fay A, Adura C, Glickman MS, Nathan C.  2016.  Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK.. Proc Natl Acad Sci U S A. 113(49):E7947-E7956.
2017
Nathan C.  2017.  Introduction of Laurie H. Glimcher, MD.. J Clin Invest. 127(10):3575.
Nathan C, Nussenzweig MC, Pulvirenti T.  2017.  JEM Advisory Editorial Board: Increasing diversity.. J Exp Med.
Nathan C.  2017.  Kunkel Lecture: Fundamental immunodeficiency and its correction.. J Exp Med. 214(8):2175-2191.
Nathan C, Nussenzweig M, Pulvirenti T.  2017.  The new face of JEM.. J Exp Med. 214(12):3467.
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.  2017.  Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..  2017.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.
Santos Rde Luna Al, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JPierre et al..  2017.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.. Nat Commun. 8(1):1692.
Gold B, Nathan C.  2017.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.. Microbiol Spectr. 5(1)